CyberKnife Treatment — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

CyberKnife is a frameless robotic stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) system that delivers precisely targeted, high-dose beams of radiation to tumours anywhere in the body using a compact linear accelerator (linac) mounted on a robotic arm. Unlike conventional radiotherapy, which delivers low doses over 20–35 sessions and requires rigid frame immobilisation, CyberKnife delivers large ablative radiation doses in 1–5 sessions with sub-millimetre accuracy (within 0.3–0.5 mm) using real-time image guidance. The system continuously tracks tumour movement during respiration (Synchrony respiratory tracking) and automatically adjusts beam delivery, compensating for organ motion without requiring patients to hold their breath. Radiation oncologists, medical physicists, and neurosurgeons collaborate in CyberKnife treatment planning and delivery. CyberKnife is FDA-cleared for treating tumours throughout the body and is installed in over 400 centres worldwide, including leading cancer centres in India, Singapore, and the USA. Unlike conventional framed radiosurgery systems (Gamma Knife), CyberKnife does not require a rigid stereotactic head frame; instead, real-time image guidance using paired orthogonal X-ray cameras tracks tumour and patient motion 30–60 times per second, with robotic compensation ensuring sub-millimetre targeting accuracy. Treatment is typically delivered in 1–5 fractions (stereotactic radiosurgery — SRS — or stereotactic body radiotherapy — SBRT), enabling ablative doses to be concentrated on the tumour while sharply sparing adjacent critical structures.

CyberKnife is indicated for patients with tumours that are inoperable (due to location or patient co-morbidities), amenable to stereotactic ablation, or where the patient prefers a non-surgical approach. Established indications include: intracranial tumours — brain metastases (1–10 lesions, each under 4 cm), meningioma, acoustic neuroma (vestibular schwannoma), AVM, pituitary adenoma, and glioma boost; spinal tumours — spinal metastases, ependymoma, and meningioma; thoracic — early-stage non-small cell lung cancer (T1–T2 N0 SBRT), lung metastases, and recurrent lung cancer after prior radiation; abdominal — liver metastases, hepatocellular carcinoma, pancreatic cancer; pelvic — prostate cancer (5-fraction SBRT), rectal cancer; and trigeminal neuralgia (functional CyberKnife to the trigeminal ganglion). Particularly valuable for re-irradiation cases where conventional retreatment carries prohibitive toxicity risk, and for patients unfit for surgery due to age, frailty, or anticoagulation. Lesion size under 5 cm is generally optimal; larger lesions may require staging.

Treatment begins 1–2 weeks before radiation delivery with a CT simulation (and MRI or PET fusion for most tumours) performed with the patient in the treatment position using customised immobilisation (thermoplastic mask for intracranial, body frame for thoraco-abdominal targets). Fiducial gold markers may be implanted in or near some tumours (lung, liver, prostate) to enable real-time X-ray tracking during treatment. The radiation oncologist and physicist delineate the target volume (GTV, PTV) and organs at risk. Inverse-planned IMRT dose distribution is optimised to deliver the prescribed dose to the tumour while minimising dose to adjacent critical structures. On treatment days, the patient lies on a flat table. Orthogonal X-ray imagers continuously acquire images every 10–30 seconds, comparing to DRRs derived from the planning CT to track tumour position with sub-millimetre accuracy. The robotic arm (with 6 degrees of freedom and 100+ non-coplanar beam angles) delivers radiation from multiple directions, creating a highly conformal dose distribution. Each session takes 30–90 minutes. Total treatment is 1 session (SRS for single brain metastasis or AVM) to 5 sessions (SBRT for prostate cancer). The patient feels nothing during beam delivery. Total treatment time per fraction is 30–90 minutes at the treatment couch. The robotic arm delivers radiation from over 100 non-coplanar beam directions.

CyberKnife delivers the radiobiological equivalent of surgical resection without anaesthesia, incisions, or hospitalisation. Patients can drive themselves to and from treatment and resume normal activities the same day. Local tumour control rates are equivalent to surgery for selected indications: 90–95% local control at 2 years for brain metastases (JAMA Oncology data), 85–90% for early-stage lung cancer at 3 years (STARS and ROSEL trials), and 95%+ for prostate cancer at 5 years with 5-fraction SBRT (HYPO-RT-PC trial). Treatment of trigeminal neuralgia achieves pain relief in 75–85% of patients. For acoustic neuroma, CyberKnife controls tumour growth in 97% at 5 years while preserving hearing in 60–70% — superior to microsurgical outcomes for hearing preservation. Medical tourism benefits are significant: CyberKnife treatment in India costs approximately INR 2,00,000–5,00,000 (USD 2,400–6,000) for a full course, compared to USD 30,000–80,000 in the USA. Leading Indian centres with CyberKnife include Fortis, Apollo, and Tata Memorial.

CyberKnife side effects depend on the tumour site, dose, and proximity to critical structures. Common effects across all sites include mild fatigue during and for several weeks after treatment. Site-specific effects include: intracranial — headache and nausea from cerebral oedema (managed with dexamethasone 4 mg daily during and after treatment), transient neurological symptoms, and radiation necrosis of adjacent brain parenchyma in 1–5% (treated with hyperbaric oxygen, bevacizumab, or surgical debulking in severe cases); lung — radiation pneumonitis in 5–15%, rib fracture (2–5% for peripheral lesions adjacent to chest wall); liver — radiation-induced liver disease in under 2% at standard doses; prostate — urinary frequency, urgency, and dysuria during and after treatment (2–4 weeks), late rectal toxicity (grade 2–3 in 3–5%). Spinal cord injury (radiation myelopathy) from spinal SBRT is rare (under 1%) when dose constraints are respected. The tumour may transiently appear larger on MRI 1–3 months post-treatment (pseudo-progression) before subsequently shrinking — this is a recognised phenomenon requiring experienced radiological interpretation.

No specific recovery period is required after CyberKnife; patients leave the treatment room immediately after each session and resume normal activities the same day. Mild fatigue may accumulate over the treatment course and typically resolves within 2–4 weeks after completing all sessions. For intracranial treatments, a short course of dexamethasone (3–5 days) reduces treatment-related cerebral oedema. Patients with prostate cancer undergoing 5-fraction SBRT may experience urinary frequency and urgency for 2–4 weeks after treatment; alpha-blockers (tamsulosin) and anti-inflammatories provide symptomatic relief. No dietary restrictions apply unless treating abdominal tumours. Tumour response assessment by MRI or CT (and PSA for prostate cancer) is performed at 3, 6, and 12 months after treatment. Brain metastasis lesions are imaged every 3 months to assess response and detect new lesions early. Most patients can continue working throughout treatment. Driving is not affected. Follow-up with the treating radiation oncologist continues for 2–5 years post-treatment.